Premium
Inhibition of carcinoma cell‐derived VEGF reduces inflammatory characteristics in xenograft carcinoma
Author(s) -
Salnikov Alexei V.,
Heldin NilsErik,
Stuhr Linda B.,
Wiig Helge,
Gerber Hanspeter,
Reed Rolf K.,
Rubin Kristofer
Publication year - 2006
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.22217
Subject(s) - angiogenesis , pathology , bevacizumab , vascular endothelial growth factor , lewis lung carcinoma , carcinoma , tumor microenvironment , inflammation , cancer research , vascular permeability , medicine , cancer , chemotherapy , immunology , metastasis , vegf receptors , tumor cells
The stroma of carcinomas shares several characteristics with inflamed tissues including a distorted vasculature, active angiogenesis and macrophage infiltration. In addition, the tumor interstitial fluid pressure ( P IF ) of the stroma is pathologically elevated. We show here that bevacizumab [rhuMab vascular endothelial growth factor (VEGF), Avastin], a monoclonal antibody to VEGF, at a dose of 5 mg/kg modulated inflammation in KAT‐4 xenograft human anaplastic thyroid carcinoma tissue. At this dose, bevacizumab reduced the density of macrophages, MHC class II antigen expression by macrophages and IL‐1β mRNA expression. Furthermore, bevacizumab lowered tumor extracellular fluid volume, plasma protein leakage from tumor vessels, the number of CD31‐positive structures and tumor P IF . The tumor plasma volume and the number of α‐smooth muscle actin‐positive vessels, however, remained unchanged. Our data suggest that carcinoma cell‐derived VEGF either directly or indirectly participates in maintaining an inflammatory microenvironment in experimental KAT‐4 carcinoma. Furthermore, our data indicate that the reduction of inflammation resulting in reduced vascular permeability and decrease in the tumor extracellular fluid volume by bevacizumab contributes to reduced tumor P IF . © 2006 Wiley‐Liss, Inc.